Sativex (THC+CBD) was as effective as baclofen for MS spasticity in a mouse model
A review described how endocannabinoid levels change in MS and found that Sativex (1:1 THC:CBD) dose-dependently reduced MS-related spasticity in mice as effectively as the standard treatment baclofen.
Quick Facts
What This Study Found
The review examined the role of endocannabinoids in MS-related muscular dysfunction and the therapeutic potential of Sativex (nabiximols), containing equal parts THC and CBD.
Endocannabinoid levels were found to be altered in both animal models of MS and in cerebrospinal fluid samples from MS patients. Anandamide and 2-AG levels changed in different and sometimes opposing ways, suggesting complex regulatory involvement.
In an experimental mouse model of MS-related spasticity, Sativex dose-dependently improved hind limb flexion and stiffness. At 10 mg/kg, Sativex was as effective as baclofen at 5 mg/kg, the most widely used anti-spasticity medication.
The author noted that Sativex acted as an "endocannabinoid system modulator" rather than simply activating cannabinoid receptors.
Key Numbers
Sativex at 10 mg/kg was as effective as baclofen at 5 mg/kg for MS-related spasticity in mice. THC:CBD ratio was 1:1.
How They Did This
Expert review examining endocannabinoid pathways in MS-related spasticity, including animal model data and patient cerebrospinal fluid studies, with focus on Sativex preclinical efficacy data.
Why This Research Matters
Demonstrating that a cannabis-based medicine could match the effectiveness of established anti-spasticity treatment in an animal model provided strong preclinical support for clinical development.
The Bigger Picture
This work contributed to the evidence base that supported Sativex approval for MS-related spasticity in multiple countries.
What This Study Doesn't Tell Us
Mouse model of spasticity may not perfectly replicate human MS. Single expert review perspective. The "modulator" mechanism was described conceptually rather than with detailed molecular evidence.
Questions This Raises
- ?How does CBD contribute to anti-spasticity effects alongside THC?
- ?Could the endocannabinoid system be targeted for other neurodegenerative conditions beyond MS?
Trust & Context
- Key Stat:
- Sativex matched baclofen effectiveness for MS spasticity in mouse model
- Evidence Grade:
- Expert review with preclinical efficacy data and patient biomarker evidence.
- Study Age:
- Published in 2011. Sativex has since been approved in multiple countries for MS-related spasticity.
- Original Title:
- Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.
- Published In:
- Expert review of neurotherapeutics, 11(4 Suppl), 9-14 (2011)
- Authors:
- Di Marzo, Vincenzo(23)
- Database ID:
- RTHC-00479
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis-based medicine help with MS stiffness?
In a mouse model, Sativex (equal parts THC and CBD) was as effective as baclofen, the standard treatment, for reducing MS-related muscle stiffness and spasticity.
What is Sativex?
Sativex (nabiximols) is a pharmaceutical spray containing a 1:1 ratio of THC and CBD derived from cannabis plants. It is approved in several countries for MS-related spasticity.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00479APA
Di Marzo, Vincenzo. (2011). Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.. Expert review of neurotherapeutics, 11(4 Suppl), 9-14.
MLA
Di Marzo, Vincenzo. "Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.." Expert review of neurotherapeutics, 2011.
RethinkTHC
RethinkTHC Research Database. "Endocannabinoid pathways and their role in multiple sclerosi..." RTHC-00479. Retrieved from https://rethinkthc.com/research/di-2011-endocannabinoid-pathways-and-their
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.